Braveheart Bio (NASDAQ:BRVE) Director Acquires 1,940,000 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Erez Chimovits purchased 1,940,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the purchase, the director owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Braveheart Bio Stock Performance

NASDAQ BRVE traded down $2.52 during trading on Tuesday, reaching $25.01. The company’s stock had a trading volume of 724,651 shares, compared to its average volume of 569,084. Braveheart Bio, Inc. has a twelve month low of $24.61 and a twelve month high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.